Tag: ejection fraction (ef)

‘Ablate and Pace’ Cuts Mortality in HF, Permanent AF

When a patient has permanent atrial fibrillation (AF) and advanced heart failure (HF), rate control therapy is an option but an “ablate-and-pace” strategy may be...

ICMs Detect Serious Arrhythmias in High-Risk Post-MI: SMART-MI

After a myocardial infarction, implantable cardiac monitors (ICMs) are sensitive for detecting serious arrhythmias in patients with cardiac autonomic dysfunction but only moderately reduced left...

Positive Top-Line Results for Empagliflozin in HFpEF

Treatment with the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance, Boehringer Ingelheim/Eli Lilly) significantly reduces the risk of cardiovascular death or hospitalization for heart failure...

Iron-Clad Benefits of CRT Seen in Reduced-EF Heart Failure

The case for the use of intravenous iron therapy for some patients with heart failure (HF) and reduced ejection fraction (HFrEF) has strengthened in recent...

Mavacamten Boosts Quality of Life in Hypertrophic Cardiomyopathy

Of patients with symptomatic, obstructive hypertrophic cardiomyopathy treated with the investigational oral agent mavacamten, more than twice as many, compared with placebo, had a very...

Sotagliflozin’s HFpEF Benefit Confirmed by New Analyses

It’s now official: The investigational sodium-glucose cotransporter (SGLT) 1/2 inhibitor sotagliflozin is the first agent clearly shown in a prespecified analysis of randomized trials to improve...

FDA Expands Sacubitril/Valsartan Indication to Embrace Some HFpEF

The US Food and Drug Administration (FDA) has approved a groundbreaking expanded indication for sacubitril/valsartan (Entresto), making it the first drug in the United States...

Training Regimens Fall Short in Trial

Exercise promotes conditioning and boosts quality of life in patients with heart failure with preserved ejection fraction (HFpEF), so different training regimens have been proposed...

First Experience With Completely Leadless CRT

Totally leadless cardiac resynchronization therapy (CRT) combining the Micra transcatheter pacing system and a WiSE-CRT system was feasible and associated with significant acute QRS reduction...

Fracking Sites Tied to Increased Heart Failure Hospitalizations

Living near hydraulic fracturing is associated with increased risk of hospitalization in people with heart failure (HF), a new study from Pennsylvania suggests. The link...

New ‘Myotropic’ Class Has Modest HFrEF Benefit

Omecamtiv mecarbil, a member of the novel myotropic drug class that improves cardiac performance, safely produced a significant but modest improvement in heart failure events...

Benefits of SGLT2 Inhibitors Seen Across Patient Subgroups

Two different SGLT2 inhibitors produced broadly consistent beneficial effects across a spectrum of patients in two recent pivotal trials: one that enrolled patients with heart...

HFSA Experts Tout Immediate Quadruple Therapy for HFrEF Patients

Start most patients newly diagnosed with heart failure with reduced ejection fraction on the disorder’s four foundational drug regimens all at once, all on the...

Vericiguat Benefits Even With High Adherence to HFrEF Meds

Vericiguat (Merck/Bayer), among the latest drugs to gain cred in heart failure (HF) with reduced ejection fraction (HFrEF), significantly benefits patients who are highly adherent...

Levosimendan Hints at Benefit in Unusual Form of Heart Failure

An inotropic and vasodilating drug with few clinical-trial victories in heart failure (HF) or other low-cardiac-output conditions showed some limited success in a specific subtype...

EXPLORER Hints at Potential New Drug Option in Obstructive HCM

An investigational drug that targets part of the molecular machinery underlying obstructive hypertrophic cardiomyopathy (HCM) can improve both symptoms and functional status in patients with...

In-hospital Start of Sacubitril-Valsartan Cost-Effective in HFrEF

Starting sacubitril-valsartan (Entresto) in patients hospitalized with heart failure with reduced ejection fraction (HFrEF) is not only cost-effective, but actually cost-saving, as compared with outpatient...

No LV Benefit in Subclinical Hypothyroidism With MI

For patients with acute myocardial infarction (MI) and mild subclinical hypothyroidism (SCH), treatment with levothyroxine does not improve left ventricular function, according to results of...

For Some, Sacubitril/Valsartan May Obviate Need for ICD

After 6 months of therapy with the combination drug sacubitril/valsartan (S/V; Entresto, Novartis), one quarter of primary prevention patients with left heart failure and an...

Inappropriate Shocks Cut by a Refined Subcutaneous ICD

FROM HEART RHYTHM 2020 Patients with an indication for an implantable cardiac defibrillator for primary prevention of sudden cardiac death and a sharply reduced left...